ReachMD

CME

Não deixe de visitar o site do podcast e apoiar quem o produz: reachmd.com

Autor

ReachMD

Categoria

Science

Site do podcast

reachmd.com

Último episódio

20 de out de 2026

Onde ouvir?

Podcasts no app Replaio Radio Em breve

Os podcasts estão chegando ao app. Instale agora e seja o primeiro a descobrir um jeito totalmente novo de curtir podcasts

Baixe no Google Play Instale grátis Android 5 mi+ downloads · nota 4,8 iOS em breve

Episódios

Brain Metastases Management: From Detection to Multidisciplinary Care 07.05.2026

Faculty: Barbara O'Brien. MD What are the key considerations when managing brain metastases in patients with breast and lung cancer? This online CME activity uses case-based discussion to examine the epidemiology and clinical burden of central nervous system (CNS) involvement and how brain metastases influence prognosis, therapeutic priorities, and treatment sequencing. Participants will eval...

DKA in the Real World: Evidence and Cases that Matter 06.05.2026

Faculty: Carol Wysham, MD Faculty: Samuel Seidu, MD, FRCP(Edin), FRCGP Recently, an international panel of experts developed objective practical recommendations on how continuous ketone monitoring could improve diabetes care. Even more recently, new data was presented on the prevalence, risk, burden, and management of DKA. Join worldwide experts as they discuss the practical application of all of...

Rethinking Secondary Stroke Prevention: The Emerging Role of Factor XI Inhibition 06.05.2026

Faculty: Mukul Sharma, MD, MSc, FRCPC Faculty: Ashkan Shoamanesh, MD, MSc, FRCPC Preventing stroke is critical, but for many patients, the fear of uncontrolled bleeding stands in the way of anticoagulation. What if we didn’t have to choose? Explore the emerging role of Factor XI/XIa inhibition and how it may redefine the balance between thrombosis and hemostasis. You’ll break down the science behi...

Putting It All Together: Challenges Addressed 01.05.2026

Faculty: David T. Rubin, MD Faculty: Ugonna Iroku, MD, MHS This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A...

Genetic Susceptibility in IBD: From Risk Genes to Clinical Impact 01.05.2026

Faculty: Michael Dolinger, MD, MBA This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrate...

Understanding the Microbiome’s Role in IBD Management 01.05.2026

Faculty: Florence Odufalu, MD This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illustrates the...

Beyond Biology: Environmental and Lifestyle Influences in IBD 01.05.2026

Faculty: Sharon Dudley-Brown, PhD, FNP-BC, FAAN, FAANP Faculty: Florence Odufalu, MD This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, a...

Targeting Inflammation in IBD: Localized vs Systemic Strategies 01.05.2026

Faculty: David T. Rubin, MD Faculty: Michael Dolinger, MD, MBA This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulatio...

Pathophysiology of IBD: The War Within 01.05.2026

Faculty: Florence-Damilola Odufalu, MD This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A 3D animation illust...

IBD Beyond Symptoms: What Community GIs Need to Know 01.05.2026

Faculty: David T. Rubin, MD Faculty: Ugonna Iroku, MD, MHS This program provides community gastroenterologists with a foundational overview of IBD, emphasizing how disease biology informs diagnosis, monitoring, and treatment selection. Faculty will cover the multifactorial drivers of disease, including genetic susceptibility, environmental exposures, the gut microbiome, and immune dysregulation. A...

Optimizing Iron Deficiency Management in CKD: IV Iron Replacement Therapy Amid the Latest KDIGO Guidelines 30.04.2026

Faculty: Brendon Neuen, MBBS, PhD Recent updates to the KDIGO 2026 Clinical Practice Guideline for the Management of Anemia in Chronic Kidney Disease (CKD) emphasized the expanded role of IV iron replacement therapy in patients with non–dialysis-dependent CKD. The updated guidance emphasizes proactive iron assessment, earlier identification of iron deficiency phenotypes, and individualized selecti...

Calming Overactive Immune Response and Reducing Inflammation with TYK2 Inhibition in Psoriasis 30.04.2026

Faculty: April W. Armstrong, MD, MPH Faculty: Melinda Gooderham, MSc, MD, FRCPC There have been exciting advances in the treatment of psoriasis. Join Drs. April Armstrong and Melinda Gooderham for this expert discussion to learn about the most recent data on TKY2 inhibitors, presented at the American Academy of Dermatology Annual Meeting in Denver, Colorado.

Emerging Focus in NAION: Sharpening Diagnostic Precision for Tomorrow’s Treatments 30.04.2026

Faculty: Prem S. Subramanian, MD, PhD Faculty: Andrew G. Lee, MD Faculty: Valerie Biousse, MD This program addresses critical practice gaps in the evaluation and management of non-arteritic anterior ischemic optic neuropathy (NAION). Faculty will review acute ischemic pathophysiology, diagnostic variability, and structured approaches to improve diagnostic accuracy and readiness for clinical trials...

Navigating KDIGO Practice Guideline Recommendations to Maximize Proteinuria Reduction in Patients With IgAN 30.04.2026

Faculty: Chee Kay Cheung, MBCHB, MRCP, PHD Faculty: Claudia Seikrit Our experts review updated KDIGO practice guideline recommendations for proteinuria reduction in IgA nephropathy (IgAN) and their implications for clinical care. Drs. Chee Kay Cheung and Claudia Seikrit examine the shift toward lower proteinuria targets (<0.3 g/day) and the rationale for earlier, more intensive intervention, em...

Advances in Hemophilia: From Joint Health to FVIII Guidelines and the Clinical Integration of Rebalancing Agents 29.04.2026

Host: Guy Young, MD Guest: Annette von Drygalski, MD, PharmD, RMSK Guest: Steven Pipe, MD Guest: Robert Sidonio Jr, MD, MSc Despite major advances in prophylaxis and supportive care, hemophilia continues to disrupt daily life, limit function, and compromise long-term well-being for many patients. Joint bleeding, subclinical bleeding, and progressive arthropathy remain important concerns, even in t...

Living With Systemic Mastocytosis: Bridging Clinical Decisions and Patient Realities 24.04.2026

Faculty: Cem Akin, MD, PhD This online CME activity explores the clinical complexity and real-world impact of systemic mastocytosis through both clinician insight and patient experience. Participants will examine the multisystem burden of this disease, challenges in diagnosis, and the importance of recognizing symptoms that are often underestimated. The program reviews current evidence-based and t...

Precision Strikes in AML: Navigating the Evolving Landscape of Targeted Therapies 23.04.2026

Faculty: Harry Erba, MD, PhD This educational series explores evolving strategies in the management of acute myeloid leukemia (AML) with a focus on targeted therapies. Faculty experts will review molecular diagnostics and guideline-driven use of FLT3 and menin inhibitors across treatment lines, including frontline, relapsed/refractory, and maintenance settings. Participants will examine clinical t...

Grooving Through Lipid Management: A New Rhythm in ASCVD Risk Reduction 21.04.2026

Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Guest: Viet Le, DMSc, MPAS, PA-C, FACC, FAHA, HF-Cert Guest: Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC Guest: Pam R. Taub, MD, FACC, FASPC On-demand webcast covering the latest advances in lipid management and atherosclerotic cardiovascular disease risk reduction, including the emerging role of lipoprotein(a), data on novel lipid-lowering the...

Enhancing Collaborative Care in Retinal Diseases: A Focus on Injection Therapies 10.04.2026

Faculty: Deepak Sambhara, MD This rebroadcast of a live regional meeting series, part of The Focused Sight Initiative: Quality Improvement Interventions in Retinal Diseases, brings together retina specialists and eye care professionals to address systemic gaps in the timely diagnosis, referral, and management of patients with retinal diseases, including age-related macular degeneration (AMD), diab...

A Seat at the HS Expert’s Table: A Master Class in Diagnosis and Treatment Advances for Hidradenitis Suppurativa 09.04.2026

Host: Leandra A. Barnes, MD Guest: Mikael Horissian, MD, MBA Guest: Katrina H. Lee, MD Guest: Venessa Peña-Robichaux, MD On-demand webcast on the pathophysiology of hidradenitis suppurativa (HS), best practices for its timely diagnosis and long-term management, and the latest data on emerging therapies.

Leveraging CGM to Its Full Potential in People with T2D 08.04.2026

Faculty: John E. Anderson, MD Faculty: Davida F. Kruger, CNP Continuous glucose monitoring (CGM) has been widely used in individuals with type 1 diabetes (T1D), and evolving guidelines increasingly recommend its use for those with type 2 diabetes (T2D) as well. However, despite these updated recommendations, real-world adoption to support T2D management has remained lower than expected. Before exp...

Transforming Care in Pediatric Patients With C3 Glomerulopathy: Targeting C3 at the Source 07.04.2026

Faculty: Richard Lafayette, MD, FACP Faculty: Ankana Daga, MD Complement-mediated kidney diseases such as C3 glomerulopathy (C3G) continue to present significant diagnostic and therapeutic challenges in nephrology for both adult and pediatric patients. Among children, this rare disease can progress to end-stage kidney disease within 10 years of diagnosis. Traditional treatment options include supp...

Shifting Gears in Cardio-Renal-Metabolic Care: Harnessing Evidence-Based Therapies to Optimize Patient Outcomes 06.04.2026

Host: Ty J. Gluckman, MD, MHA, FACC, FAHA, FASPC Guest: Stephen J. Greene, MD, FACC, FHFSA Guest: Anne Louise Peters, MD On-demand webcast on best practices for optimizing guideline-directed medical therapy in cardiovascular-renal-metabolic (CRM) care and employing SGLT2 inhibitors to treat patients with CRM conditions, including heart failure.

The Future of HNSCC: Aligning Teams, Transforming Care 31.03.2026

Faculty: Ravindra Uppaluri, MD, PhD Faculty: Nancy Lee, MD, FASTRO This activity reviews data from the KEYNOTE-689 and NIVOPOSTOP trials evaluating perioperative immune checkpoint inhibition in resectable, locally advanced head and neck squamous cell carcinoma (HNSCC). Experts examine trial design, efficacy outcomes, and the role of PD-L1 combined positive score (CPS) in patient selection. Drs. Up...

Navigating Today and Shaping Tomorrow in ISM: Personalized Strategies With Current and Emerging KIT Inhibitors 31.03.2026

Faculty: Mariana C. Castells, MD, PhD Faculty: Tsewang Tashi, MD This online educational activity explores the evolving role of KIT-targeted tyrosine kinase inhibitors (TKIs) in indolent systemic mastocytosis (ISM). Expert faculty discuss pivotal clinical data supporting the approval of avapritinib, a potent TKI that targets KIT D816V, in patients with ISM. They also highlight emerging clinical ev...

Ouça o podcast CME no Replaio

Rádio e podcasts em um só app - grátis e sem cadastro. Instale hoje e não perca o lançamento

Baixe no Google Play

O Replaio não é o publicador dos podcasts; os nomes dos programas, as capas e o áudio pertencem aos seus autores e são distribuídos por feeds RSS públicos